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Broad resonances at 2.04 and 2.08 ppm in 500 MHz Hahn spin-echo ‘H NMR spectra of human blood 
plasma are assigned to the N-acetyl groups of mobile carbohydrate side-chains (largely I%‘-acetylglucosamine 
and N-acetylneuraminic acid) of glycoproteins uch as q-acid glycoprotein. Their intensities in spin-echo 
spectra correlate with clinical conditions in which an elevation of the level of ‘acute-phase’ glycoproteins 
is expected, and so may be of value in the study of certain diseases. 
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1. INTRODUCTION 
High resolution ‘H NMR spectra of human 
blood plasma can provide useful biochemical and 
clinical information [l-3]. By suppression of 
broad resonances from high molecular mass 
plasma constituents (such as albumin), using spin- 
echo Fourier transform (SEFT) methods, it is 
possible to obtain a profile of mobile protons, 
mostly low molecular mass non-protein-bound 
metabolites, present in human plasma at concen- 
trations >O.l mM [1,2]. 
We have previously assigned most of the major 
resonances in ‘H NMR spectra of human and 
animal plasmas [ 11. However, comparatively 
broad peaks centred at 2.04 ppm and at 2.08 ppm 
have not been assigned to any common low 
molecular mass component, and have aroused par- 
ticular interest by the constancy of both their 
relative intensities and their chemical shifts in the 
many plasma samples we have so far studied. 
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We report here the assignment of these peaks to 
the N-acetyl protons of highly mobile (in NMR 
terms) N-acetylated carbohydrate side-chains 
associated with ‘acute-phase’ plasma glycopro- 
teins. The intensities of the resonances from these 
protons appear to be perturbed in spin-echo spec- 
tra of plasma taken from subjects with certain ab- 
normal clinical conditions. Further studies of these 
signals may shed new light on the biochemistry of 
acute-phase glycoproteins and give insight into 
associated diseases or pathological processes. 
2. MATERIALS AND METHODS 
2.1. Proton NA4R spectroscopy 
All spectra were acquired using a Bruker AM500 
spectrometer operating at 500 MHz with 
quadrature detection, probe temperature 298 K. 
Broad protein resonances from plasma were 
suppressed using the Hahn spin-echo pulse se- 
quence (SEFT), (900-t-1800-t-collect), with a t 
value of 60 ms [ 1,4,5]. Spectra were typically the 
result of 32-48 repetitions of this sequence with a 
5-s delay between cycles. The large water signal 
was suppressed, where present, by the application 
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of continuous secondary irradiation at water fre- 
quency with the decoupler coils. An exponential 
function corresponding to a line-broadening of 
1 Hz was applied to the FID prior to Fourier 
transformation. 
2.2. Sample collection and preparation 
Human plasma glycoproteins &-acid glycopro- 
tein, cui-antitrypsin, transferrin, haptoglobin and 
immunoglobulins) were purchased from Sigma. 
Each glycoprotein was dissolved in deuterium ox- 
ide (DzO) and the pH of the solution adjusted to 
pH 7.2 (meter reading) with 10 M NaOD. Both 
single pulse and SEFT spectra were obtained from 
these samples using either endogenous alanine (S = 
1.48 ppm) or added sodium 3-(trimethylsilyl)-2,3- 
tetradeutero-propionate, TSP (S = 0.00 ppm), as a 
chemical shift reference. Spectra were similarly 
acquired from samples of N-acetylneuraminic acid 
and N-acetylglucosamine (Sigma). 
Blood was obtained from a number of con- 
senting healthy volunteers (> 10 adults, both males 
and females) and placed in sterile plastic vials con- 
taining lithium heparin. The blood was centrifuged 
at 4°C immediately and the plasma separated and 
stored at -20°C. Samples were thawed at room 
temperature prior to NMR measurement. Samples 
were also collected from subjects undergoing 
diagnostic tests for various clinical disorders in- 
cluding six patients with monoclonal gam- 
mopathy, i.e. raised immunoglobulin (IgG, IgA, 
IgM and IgE) levels, one subject with melanoma, 
and five subjects with rheumatoid arthritis. Paired 
plasma samples obtained at birth from both 
mother and cord were also collected (> 10 pairs). 
To estimate the concentration of (NMR- 
observable) acute-phase glycoproteins in blood 
plasma by NMR, standard additions were made of 
a mixture of &i-acid glycoprotein, cYi-antitrypsin, 
haptoglobin and transferrin respectively (The 
percentages of N-acetylglucosamine and sialic acid 
in these proteins (w/w) are 25.0, 3.4, 10.0 and 3.6, 
respectively [6]. Therefore @i-acid glycoprotein is 
likely to be the main source of N-acetyl sugars.) 
with a composition close to the average reported 
for human plasma [7] (0.8:3.0: 1.0: 3.0 by wt). 
Peak intensities were compared by weighing paper 
traces. 
Plasma and standard &i-acid glycoprotein 
samples were treated with the enzyme 
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neuraminidase (Vibrio cholerae, Boehringer 
Mannheim; 300 units per ml of sample) for 4 h, 
followed by treatment with&galactosidase (bovine 
liver, Sigma; 10 units per ml) and ,&N-acetyl- 
glucosaminidase (Jack beans, Sigma; 5 units per 
ml) for 12 h, at 37°C. The resulting solutions were 
ultrafiltered with Amicon centrifree micropartition 
devices (C 10 kDa cut-off). ‘H NMR spectra were 
acquired for these reaction mixtures, as well as 
their ultrafiltrates. 
3. RESULTS 
The ‘aliphatic’ region (O-4.2 ppm) of the SEFT 
500 MHz ‘H NMR spectrum of human &i-acid 
glycoprotein is shown in fig.la. Broad resonances 
from the protein component of the glycoprotein 
are suppressed in the SEFT spectrum, only signals 
from protons with long TZ values, which can be 
associated with very mobile protons, are observed. 
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Fig.1. 500 MHz spin-echo (t = 60 ms) ‘H NMR spectra 
of the aliphatic region of (a) normal human blood 
plasma and (b) cur-acid glycoprotein in D20. In (a) most 
of the assignments of the peaks for plasma have been 
reported previously [1,2]. Peaks Pi and Pz, and P3 arise 
from the CH, and CH2 groups, respectively, of 
lipoprotein components. The inset (c) shows that the 
reported chemical shift ranges [10,11,13] for the N- 
acetyl groups of N-acetylglucosamine (0) and N- 
acetylneuraminic acid (-) of the isolated 
carbohydrates of human plasma glycoproteins cover the 
range from 2.0-2.1 ppm and can be correlated with the 
position of the sugar in the branching chains 
(1,2,5,5’ ,7). 
Volume 215, number 2 FEBS LETTERS May 1987 
The most intense resonance in the spectrum is com- 
paratively broad and centred at 2.04 ppm with a 
weaker shoulder centred at 2.08 ppm. Weak 
signals are also observed in the 3.0-4.0 ppm 
region of the SEFT spectrum, where signals from 
sugar CH protons usually occur. Similar 
resonances were observed in the spectra of the 
other plasma glycoproteins studied (see section 2), 
except for immunoglobulins for which none were 
seen under these conditions. 
The ‘aliphatic’ region of the SEFT 500 MHz ‘H 
NMR spectrum of normal human plasma is shown 
in fig.lb. The majority of the signals in this spec- 
trum have been identified previously [ 1,2]. The 
distinctive broad resonances centred at 2.04 ppm 
(resonance I: Avr/z = 8.0 Hz) and 2.08 ppm 
(resonance II: A~i/2 = 11.9 Hz) are almost iden- 
tical to those seen for al-acid glycoprotein (fig. la). 
The plasma components which give rise to these 
signals did not pass through an ultrafiltration 
membrane with a cut-off of 10 kDa. By ‘spiking’ 
a plasma sample with &i-acid glycoprotein, a clear 
increase in intensity of these signals was observed 
(not shown). Similar results were obtained by spik- 
ing with other ‘acute-phase reactive’ plasma 
glycoproteins, including ai-antitrypsin, hap- 
toglobin and transferrin. These proteins all have 
molecular masses in the range 40-100 kDa [7]. 
Addition of known quantities of a plasma 
glycoprotein mixture (see section 2) suggested that 
the concentration of glycoproteins responsible for 
the signals I and II was -13 mg/ml in the plasma 
of normal subjects. 
The resonances of the sugar ring protons of the 
glycoproteins were not clearly discernable in any of 
the plasma spectra studied, because of extensive 
overlap with the more intense signals from glucose. 
In fig.2a and b, SEFT spectra of plasma before 
and after treatment with a mixture of neuramini- 
dase, galactosidase and N-acetylglucosaminidase 
are compared. A number of new resonances are 
clearly observed in the latter spectrum, including a 
marked increase in intensity of the signal at 
2.06 ppm. Similar results were obtained with en- 
zymatically treated glycoprotein solutions. ‘H 
NMR spectra of the ultrafiltrate (< 10 kDa) ob- 
tained after these enzymatic reactions, suggested 
that the new resonances could be assigned to ‘free’ 
N-acetylneuraminic acid and N-acetylglucosamine. 
The signal intensity of the resonance at 2.04 ppm 
(I) was reduced to less than 30% of its original in- 
tensity after the enzymatic treatment of plasma 
and glycoprotein samples. 
Fig.3a and b compare the SEFT ‘H NMR spec- 
tra of mother and paired cord plasma obtained at 
birth. The intensities of peaks I and II in the spec- 
trum of maternal plasma exceed those from the 
2.5 2.0 mm 1.5 
Fig.2. 500 MHz ‘H NMR spin-echo spectra of human 
blood plasma (a) before and (b) after treatment (at pH 
5) with neuraminidase followed by galactosidase and 
glucosaminidase (see section 2). The plasma had been 
freeze-dried to remove Hz0 which caused a rise in pH 
(to 8.6) and the small shift of the Ala CHs resonance [l]. 
The appearance of resonances for free sugars after 
enzyme treatment is indicated by arrows in b. 
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Fig.3. 500 MHz ‘H NMR spin-echo spectra of a 
matched pair of (a) cord and (b) maternal blood plasma 
taken at birth. Note the large increase in intensity of the 
IV-acetyl signals in b. The spectra have been plotted with 
the Ala CH3 resonance as the intensity standard. The 
other differences in these spectra will be discussed 
elsewhere (Brown, J.C.C. et al., to be published). 
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kig.4. 500 MHz ‘H NMR spin-echo spectra of human 
blood plasma from the following subjects: (a) 
melanoma, (b) normal, (c) rheumatoid arthritic and (d) 
monoclonal gammopathy (elevated IgG levels). Changes 
in the relative intensities of the N-acetyl resonances I and 
II are discussed in the text. The significance of changes 
in the intensities of other resonances will be discussed 
elsewhere. 
cord plasma by a factor of 2.2 f 0.5 in the 10 pairs 
studied (Brown, J.C.C. et al., unpublished). The 
intensities of these peaks in spectra of maternal 
plasma also appear to exceed those in spectra from 
non-pregnant women. 
Fig.4 shows a similar comparison of spectra for 
plasmas obtained from a healthy subject, and sub- 
jects with melanoma, rheumatoid arthritis and a 
monoclonal gammopathy. The intensities of peaks 
I and II in the spectra of plasma from subjects with 
melanoma and rheumatoid arthritis exceed those 
of the normal plasma. These peaks appeared nor- 
mal for subjects with monoclonal gammopathy 
(IgC) . 
4. DISCUSSION 
Providing appropriate checks are made for 
possible distortions due to differential T2 relaxa- 
tion effects, comparison of the areas of glycopro- 
tein N-acetyl signals with those of added standards 
(e.g. alanine) can give an indication of differences 
in glycoprotein levels in plasma samples. 
The enzymes neuraminidase, galactosidase and Thus, the ‘H NMR measurements suggested that 
N-acetylglucosaminidase cleave the terminal N- raised levels of acute-phase glycoproteins are pre- 
acetylneuraminic acid, galactose and N-acetyl- sent in maternal plasma compared to cord plasma. 
glucosamine residues, respectively, of polysaccha- This agrees with literature reports that maternal 
rides [8]. The addition of these enzymes to plasma plasma glycoprotein concentrations increase at 
samples and glycoprotein solutions gave rise to 
several new resonances in the spectrum, which 
were assigned to N-acetylneuraminic acid and N- 
acetylglucosamine, both of which are components 
of most plasma glycoproteins [9-111. Thus, the 
plasma signals centred at 2.04 (I) and 2.08 (II) ppm 
appear to arise from the N-acetyl groups of N- 
acetylglucosamine and N-acetylneuraminic acid 
and give rise to the sharp N-acetyl peak at 
2.06 ppm after enzymatic treatment. 
Previous studies on the extracted carbohydrate 
moieties of plasma glycoproteins (including 
ai-acid glycoprotein) have shown that these can 
give rise to peaks for N-acetyl groups with shifts in 
the chemical shift range 2.00-2.10 ppm depending 
on their position in the branched polysaccharide 
chain (see inset to fig.1). This accounts for the ap- 
parent broadness (and yet long TZ values, 
- 450 ms) of peaks I and II [9- 131. 
The carbohydrate side-chains of these glycopro- 
teins appear to be highly mobile compared to the 
protein. Indeed, they are not seen in electron densi- 
ty maps of crystalline lactoferrin, due to their high 
temperature factors (B. Anderson, personal com- 
munication). 
Human plasma contains many N-acetylated 
glycoproteins including cYi-antitrypsin, transferrin, 
haptoglobin, al-acid glycoprotein (acute-phase 
glycoproteins), immunoglobulins and fibrinogen 
[8,12,13]. Our studies suggest hat the resonances 
at 2.04-2.08 ppm (I and II) in human plasma spec- 
tra originate from N-acetyl groups of N-acetylated 
carbohydrate side-chains present in the acute- 
phase reactive plasma glycoproteins. The concen- 
tration of some of these plasma glycoproteins are 
known to change in a number of clinical disorders, 
e.g. inflammation, cancer, rheumatoid arthritis, 
some liver diseases, trauma, and also during 
pregnancy and at birth [14-191. 
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birth while cord levels are one-third those of nor- 
mal adults. However, the clinical significance of 
these changes is unclear [14]. 
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